W-L Announces Three-For-One Stock Split

27 November 1997

The board of directors at Warner-Lambert has voted in favor of athree-for-one stock split of common stock, subject to shareholder approval, increasing the number of authorized common shares from 500 million to 1.2 billion. If approved, the split will take place on May 8, 1998, while shares will be distributed two weeks later.

Melvin Goodes, Warner-Lambert's chairman and chief executive, said that he fully expected the company's sales and earnings growth to continue well into the next century, and added that the stock split, the second in two years, "reflects our utmost confidence that our company's greatest days lie ahead."

Analyst Not Surprised Warner-Lambert stock has been one of the best in the drug sector, and especially now, thanks to the success of its new prescription drugs, claims David Saks of analysts Gruntal & Co, who told the Marketletter that "it didn't take a rocket scientist to know this was coming."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight